Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Completed · Phase 1

Conditions studied: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

In brief

This was a Phase 1, multicenter, open-label, clinical trial in adult subjects with metastatic castrate resistant prostate cancer who progressed after both hormonal therapy (abiraterone or enzalutamide) and chemotherapy (docetaxel), or cannot tolerate either or both therapies. The study involved a Phase 1 dose escalation of oral GT0918 to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics.

Key facts

Study ID

NCT02826772

Run by

Suzhou Kintor Pharmaceutical Inc,

People needed

40

Starts

2016-02-10

Expected to finish

2020-02-15

Last updated by the study team

2020-03-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained prior to any study-related procedure being performed.
• Subjects at least 18 years of age or older at the time of consent.
• Histologically confirmed metastatic castrate resistant cancer (mCRPC) who progressed after both hormonal therapy (abiraterone or enzalutamide) and chemotherapy (docetaxel, for example); or cannot tolerate either or both of these classes of therapies.
• Ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone (LHRH) "super-agonist" or antagonist, or bilateral orchiectomy and serum testosterone level < 50 ng/dL (< 0.5 ng/mL, < 1.7 nmol/L) at screening.
• Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
• Progressive disease despite ongoing androgen deprivation or chemotherapy. Progressive disease is defined by 1 or more of the following criteria:
• Subjects with a rising PSA value > 2 ng/mL in at least 2 measurements, at least 1 week apart. If the confirmatory PSA value is less than the screening PSA value, then an additional test for the rising PSA is required to document progression.
• Subjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
• Subjects with metastatic bone disease, progression defined by 2 or more new lesions in a radionuclide bone scan.
• ECOG performance status of 0-2 (dose escalation phase); ECOG performance status of 0-1 (expansion phase).
• Screening blood counts of the following:
• Absolute neutrophil count ≥ 1500/μL
• Platelets ≥ 100,000/μL
• Hemoglobin > 9 g/dL
• Screening chemistry values of the following:
• Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper limit of the normal reference range (ULN)
• Total bilirubin ≤ 2 × ULN
• Creatinine ≤ 1.5 × ULN
• Albumin > 2.8 g/dL.
• At screening, life expectancy of at least 3 months.
• Subjects whose partners are women of childbearing potential (WOCBP) must use an adequate method of birth control while on study drug and at least for 3 weeks after discontinuation of study drug.
• Subject is willing and able to comply with all protocol required visits and assessments.

You may not qualify if…

• Subjects with life expectancy less than 3 months.
• Discontinuation of bicalutamide or nilutamide less than 6 weeks, and other antiandrogens less than 4 weeks, abiraterone less than 3 weeks, prior to the start of study medication.
• Prior chemotherapy, radiation, sipuleucel-T or other experimental immunotherapy less than 4 weeks prior to the start of study medication.
• Prior chemotherapies more than 2 lines (Phase II part only) .
• Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy.
• History of impaired adrenal gland function (eg, Addison's disease, Cushing's syndrome).
• Known gastrointestinal disease or condition that affects the absorption of GT0918.
• History of congestive heart failure New York Heart Association (NYHA) class III or IV or uncontrolled hypertension at screening.
• History or family history of long QT syndrome.
• History of other malignancy within the previous 3 years, except basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.
• Use of systemic glucocorticoid (eg, prednisone, dexamethasone) within 14 days prior to the start of study medication.
• Co-administration of CYP3A4 ligands that serve as substrates or induce or inhibit the enzyme.
• Prior use of any herbal products known to decrease PSA levels (eg, PC-SPES or saw palmetto) within 30 days prior to the start of study medication.
• Major surgery within 30 days prior to the start of study medication.
• Blood transfusion (including blood products) within 1 week of screening.
• Serious persistent infection within 14 days prior to the start of study medication.
• Serious concurrent medical condition including CNS disorders.
• Previous history of difficulty swallowing capsules.
• Known hypersensitivity to GT0918 or its excipients.
• Any condition that, in the opinion of the investigator, would impair the subject's ability to comply with study procedures.

Where it is running

• Chesapeake Urology Research Associates — Towson, Maryland, United States
• G U Research Network — Omaha, Nebraska, United States
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
• Rutgers University — New Brunswick, New Jersey, United States
• North Shore Hematology Oncology Associates — East Setauket, New York, United States
• Gabrail Cancer Center Research — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.